Abbott’s new Volt PFA System has received FDA approval for treating atrial fibrillation, marking a significant advancement in cardiac care that could benefit millions of Americans suffering from the condition.
The approval, announced on December 22, 2025, follows the VOLT-AF IDE study involving 392 patients across 40 centers in the United States, Europe, Canada, and Australia. The system represents a breakthrough in AFib treatment technology, combining gentler heart therapy with shorter procedure times.
A New Approach to a Growing Problem
Could this be the game-changer cardiologists have been waiting for? The Volt PFA System is designed as an all-in-one solution that integrates with Abbott’s EnSite X EP System, potentially transforming how doctors approach one of America’s most common cardiac conditions.
Approximately 12 million Americans over age 65 currently suffer from atrial fibrillation, with that number expected to double over the next two decades. AFib patients face a fivefold increased risk of stroke, making effective treatment crucial. The condition manifests in two forms that were both addressed in clinical trials: paroxysmal atrial fibrillation (episodes that come and go) and persistent AFib (episodes lasting longer than seven days).
“Volt is a promising option for patients,” stated Dr. DJ Lakkireddy. “Its real-time contact visualization and unique balloon-in-basket design provide superior tissue contact and focused energy delivery, while addressing some of the limitations of the early generation PFA systems.”
Technical Advantages
What sets the Volt system apart from competitors is its efficiency. Clinical data shows the system requires an average of just 4.7 applications per vein—fewer than competing PFA systems. This precision aims to achieve more durable lesions with fewer pulses, potentially reducing the need for repeat procedures.
The technology also reduces radiation exposure through decreased fluoroscopy requirements and limits hemolysis (the breakdown of red blood cells) during ablation procedures compared to traditional approaches.
These features aren’t just technical improvements—they translate to meaningful patient benefits. Dr. Christopher Piorkowski highlighted that “The Volt PFA System is an option for patients who prefer conscious sedation, which can also lead to faster recovery times and shorter procedures for the millions of Americans who suffer from an abnormal heart rhythm.”
Promising Clinical Data
The system’s approval follows compelling clinical evidence. Beyond the primary VOLT-AF IDE study that led to FDA approval, the Volt CE Mark Study demonstrated sustained 12-month safety and efficacy data with impressive results: 93.8% first-pass isolation achieved and 100% acute effectiveness in the zero-fluoro group with zero safety events among the 16 patients studied.
That performance helped Abbott secure CE Mark approval in Europe in March 2025, several months before the FDA gave its green light. The company will now begin commercial PFA cases in the United States while continuing expansion across European Union sites.
The technology’s ability to deliver precise, targeted energy during ablation procedures appears to be its main advantage. By achieving durable lesions with fewer pulses, the system aims to support effective first-time procedures while minimizing complications—a significant consideration for both patients and healthcare systems concerned with reducing readmissions and repeat procedures.
For the millions of Americans living with the irregular heartbeats, shortness of breath, and fatigue that characterize AFib, Abbott’s new system offers something increasingly rare in healthcare: a treatment option that might be both more effective and less invasive than what came before.
